On July 20, Elevance Health rose 3.08% in regular trading, trading near $385.11/share, with turnover of approximately $74.15 million. The stock continued its recovery from the post-Q2 earnings sell-off.

The rebound is being driven by a wave of analyst price target increases following the company's strong Q2 results. Guggenheim raised its target to $455, Truist to $475, and Leerink to $395. Truist lifted its full-year EPS estimate to $27.12 and its fiscal year forward estimate to $29.14, citing Q2 outperformance and improved guidance as a foundation for long-term expectations. The company reported Q2 adjusted EPS of $7.45, beating consensus of $6.21 by nearly 20%, and raised full-year adjusted EPS guidance to at least $27.00.

Despite the beat, the stock had initially fallen approximately 10% on the earnings release date due to concerns over Medicaid utilization pressure and planned market exits over the next 12-18 months. The current move reflects a normalization as the Street digests the magnitude of the earnings surprise against the Medicaid headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)